Adjuvant pembrolizumab prolongs overall survival in renal cell carcinoma at high-risk of recurrence after nephrectomy. Can we do better than this?

Autor: Ciccarese C; Medical Oncology Unit, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy., Mollica V; Medical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy - veronica.mollica7@gmail.com., Marandino L; Medical Oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK., Palumbo C; Unit of Urology, Maggiore della Carità Hospital, Novara, Italy., Campi R; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.; Urological Robotic Surgery and Renal Transplantation Unit, Careggi Hospital, University of Florence, Florence, Italy., Amparore D; Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy.
Jazyk: angličtina
Zdroj: Minerva urology and nephrology [Minerva Urol Nephrol] 2024 Oct; Vol. 76 (5), pp. 540-544.
DOI: 10.23736/S2724-6051.24.06114-7
Databáze: MEDLINE